Kymab Ltd | Home

Advanced therapeutic antibody discovery & development

Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering transgenic mouse platform. We are building a rich pipeline of assets in 3 therapeutic spaces: immuno-oncology, immunology and opportunistic.

Perfecting discovery

Kymouse™ is transforming the discovery of very high affinity fully human monoclonal antibodies against a broad range of drug targets and has been designed to overcome the limitations of previous humanised transgenic antibody platforms.


Kymab discovers and develops its drugs both independently and in collaboration with pharmaceutical, biotechnology and academic partners. We are employing our proprietary technologies, including Kymouse™ to discover, develop and commercialise monoclonal antibody medicines to difficult and novel drug targets.